239 related articles for article (PubMed ID: 24850846)
21. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.
Ferenczi K; Ohtola J; Aubert P; Kessler M; Sugiyama H; Somani AK; Gilliam AC; Chen JZ; Yeh I; Matsuyama S; McCormick TS; Cooper KD
Br J Dermatol; 2010 Sep; 163(3):564-71. PubMed ID: 20408834
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
23. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS
J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399
[TBL] [Abstract][Full Text] [Related]
24. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
25. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
26. Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
Ion A; Popa IM; Papagheorghe LM; Lisievici C; Lupu M; Voiculescu V; Caruntu C; Boda D
Dis Markers; 2016; 2016():9602472. PubMed ID: 27821903
[TBL] [Abstract][Full Text] [Related]
27. Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease.
Borowitz MJ; Weidner A; Olsen EA; Picker LJ
Leukemia; 1993 Jun; 7(6):859-63. PubMed ID: 7684799
[TBL] [Abstract][Full Text] [Related]
28. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
31. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
32. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
33. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.
Wei T; Biskup E; Gjerdrum LM; Niazi O; Ødum N; Gniadecki R
Oncotarget; 2016 Jul; 7(30):48391-48400. PubMed ID: 27351221
[TBL] [Abstract][Full Text] [Related]
34. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
35. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
37. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas.
van Haselen CW; Vermeer MH; Toonstra J; van der Putte SC; Mulder PG; van Vloten WA; Willemze R
J Cutan Pathol; 1997 Sep; 24(8):462-7. PubMed ID: 9331891
[TBL] [Abstract][Full Text] [Related]
38. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
40. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]